Previous 10 | Next 10 |
Kubient KBNT -21% on Q2 2020 Results Earnings call.Nikola NKLA -12% after WSJ warns on stalled talks with potential partners.NanoVibronix (NAOV) -10%.Golar LNG (GLNG) -9%.Digital Ally (DGLY) -8%.DiamondPeak Holdings (DPHC) -8%.AIM ImmunoTech (AIM) -7%.Pen...
Are Analysts Correct About These Penny Stocks To Buy Right Now? Penny stocks are some of the most interesting types of stocks to watch. This is the case for several reasons. For one, these stocks are known to be quite volatile. For those who use day or swing trading, volatility is p...
Gainers: NanoVibronix (NAOV) +98%, AIM ImmunoTech (AIM) +29%, Rockwell Medical (RMTI) +22%, Aurora Cannabis (ACB) +16%, Allied Healthcare Products (AHPI) +15%.Losers: Vaccinex (VCNX) -56%, BioSig Technologies (BSGM) -30%, ADC Therape...
Gainers: NanoVibronix (NAOV) +106%.Carvana (CVNA) +33%.AIM ImmunoTech (AIM) +25%.GameStop (GME) +21%.Boxlight (BOXL) +20%.Rockwell Medical (RMTI) +20%.Blink Charging (BLNK) +19%.Natural Alternatives International (NAII) +18%.Issuer Direct (ISDR) +17%.Renren (RENN) +16%.Losers:&...
AIM ImmunoTech (AIM) jumps 35% premarket on robust volume in reaction to its announcement of results from an Ampligen multiyear early access program in the Netherlands for pancreatic cancer patients.A medical team at Erasmus University Medical Center ((EUMC)) reported a significant ...
Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer OCALA, FL / ACCESSWIRE / September 22, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announ...
AIM ImmunoTech (NYSEMKT: AIM ) begins recruitment in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19. More news on: AI...
OCALA, FL / ACCESSWIRE / September 16, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that recruitment has begun in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b...
OCALA, FL / ACCESSWIRE / September 10, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020. Thomas K. Equels, Chief Executive Officer of A...
Intra-Cellular Therapies (ITCI +74% on positive topline results from its Phase 3 clinical trial. More news on: Astrotech Corporation, Vaxart, Inc., Chembio Diagnostics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...